During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

Abecma US Revenue: $77 million in the third quarter, reflecting a 42% growth over the prior quarter. Projected Abecma US Revenue for 2024: Approximately $240 to $250 million. Collaboration Arrangement ...

Seventy Bio, Inc. ( (TSVT) ) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its ...

News release. Janssen. February 28, 2022. https://bit.ly/35yWwjv U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s ...

2seventy Bio focuses on pioneering cell and gene therapies. Its lead product, Abecma, is a chimeric antigen receptor (CAR) ...

Altair , a global leader in computational intelligence, has entered into collaboration agreement with the European Space Agency (ESA) through the ESA Partnership Initiative for Commercialisation (EPIC ...

Senstar Technologies Corporation , a leading international provider of comprehensive physical, video and access control security products and solutions, today announced its financial results for the ...

CAMBRIDGE, Mass., November 12, 2024--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent ...

The latest announcement is out from 2seventy bio ( (TSVT) ). 2seventy bio reported impressive third-quarter results with a 42% increase in ...

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

BMY’s cell therapy Abecma, marketed with 2seventy bio (TSVT), generated $124M with ~33% YoY growth. On a non-GAAP basis, Bristol-Myers’ (NYSE:BMY) gross margin dropped to 77.3% from 76.0% in ...